Development of a serological test for detection of Middle East Respiratory Syndrome Coronavirus

Select | Print


McNabb, Leanne ORCID ID icon; Durr, Peter ORCID ID icon; Lunt, Ross; Adams, Tim ORCID ID icon; Bowden, Tim ORCID ID icon


2018-11-15


Conference Material


Fourteenth Annual Meeting of the Australian Association of Veterinary Laboratory Diagnosticians, Melbourne Convention and Exhibition Centre, 15-16 November


15 slides


MERS (Middle East Respiratory Syndrome) is a viral respiratory disease in humans caused by the MERS-coronavirus (MERS-CoV) and has a mortality rate of 36%. MERS-CoV is a zoonotic virus that has been identified in camels in the Middle East, and can be transmitted to humans through direct or indirect contact with infected camels. There is no vaccine or specific treatment available against MERS-CoV. To enhance our serodiagnostic capability for the virus we developed an indirect ELISA using purified expressed recombinant S1 protein as coating antigen. Preliminary assay performance characteristics were determined using 20 positive camel sera from Dubai, 288 negative alpaca sera from Chile and 300 negative camel sera from Australia. The assay performed comparably to a more expensive commercially available ELISA, which is also based on recombinant S1 protein, and offers the prospect of a reliable and standardised antibody detection capability for this recently emerged zoonosis.


Conference workbook


Veterinary Diagnosis and Diagnostics


EP1810078


Oral Presentation – Formal


English


McNabb, Leanne; Durr, Peter; Lunt, Ross; Adams, Tim; Bowden, Tim. Development of a serological test for detection of Middle East Respiratory Syndrome Coronavirus. In: Fourteenth Annual Meeting of the Australian Association of Veterinary Laboratory Diagnosticians; 15-16 November; Melbourne Convention and Exhibition Centre. Conference workbook; 2018. 15 slides. csiro:EP1810078. http://hdl.handle.net/102.100.100/86259?index=1



Loading citation data...

Citation counts
(Requires subscription to view)